Baird lowered the firm’s price target on Editas Medicine (EDIT) to $4 from $8 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results where its IP update provided incremental newsflow.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EDIT:
- Editas Medicine: Hold Rating Amid Legal Uncertainty and Financial Concerns
- Buy Rating for Editas Medicine: Promising Advancements in In Vivo Gene Editing
- Editas Medicine reports Q1 EPS (92c), consensus (59c)
- Editas Medicine expects cash to fund operations into Q2 of 2027
- Editas says U.S. Court of Appeals remands CRISPR patent interference decision